This is a good piece of reporting about a recent study comparing two different insertion sites to obtain access for angioplasty. While not providing any insight about the specific circumstances when there may be medical reasons to chose one access site over another, the story did a nice job of informing readers that there might actually be a choice when having an angioplasty. It provided information that a reader could use to have a conversation with a doctor about the decision. However – the story should have included some insight about the strength of the observation obtained from the current study. As it was not a controlled study – so it did not evaluate the two procedures in a controlled environment – any predictions are tentative and require further examination.
Overall, though, this was a balanced, clear and concise story about an approach that might be a safer alternative to the dominant way of doing an angioplasty. The story included an independent expert to comment on the study. And it reported absolute rates as well as relative rates so the reader can really get a sense of the safety of the new procedure.
The story did not provide cost estimates for either approach; the story did mention that the through-the-wrist approach was associated with shorter hospital stays (and therefore reduced costs.) There was no discussion in the story about whether there are different costs associated with the procedure itself.
The story explained that the through-the-wrist approach was associated with lower risk of bleeding and shorter hospitalizations but should have included a caveat explanation about the strength of research and that the results of the study reported on require follow-up investigation.
The story mentioned risk of bleeding at the site of catheter insertion as a possible harm of treatment which was greater for those who had a the catheter inserted in the leg. To its credit, the story provided absolute risk information, i.e. pointing out the 60% reduction in bleeding was the difference between 2 and 1% of patients having this complication.
The story did not mention whether there were any particular side effects or harms associated with catheter insertion at the wrist.
The story explained that the study was an analysis of information contained within a national registry. But it should have explained that this is the weakest type of study from which to draw a clinical conclusion (such as this procedure is safer or as safe as the alternative). Thus the statement in the story ‘both methods were equally effective’ should have been more tentative. The underlying weakness of the study, that it is not a controlled trial, may mean that the patients who had the wrist approach had something else about them that helped to reduce risk and that the researchers may not have been able to take into consideration.
The story did not engage in overt disease mongering.
The story included interview material from one clinician who was not associated with the study reported on. The quality of the piece would have been improved if it had included input from physicians who might have explained some of the reasons why not all interventional cardiologists use the wrist approach.
The story did an adequate job of reporting about a recent study comparing two approaches to angioplasty.
The story indicated that the angioplasty using access through the wrist as opposed to a leg, was used much less frequently.vThe story explained that extra training is required in order to use this procedure and many doctors are not trained in this technique. This would contribute to the procedure’s limited availability.
The story did a good job of explaining that neither of the two approaches compared were new and that the point of the study was to determine how the two sites compare in terms of their use.
The story does not appear to rely exclusively on a press release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like